Tag Archive for: migraine drug

Data from the Phase III PRODROME study showed that AbbVie’s migraine drug Ubrelvy (ubrogepant), when given ahead of an expected episode, safely and effectively reduces the likelihood of developing moderate or severe headache, the company reported Thursday.

AbbVie shared more positive results for its migraine prevention drug, Qulipta, just three days after FDA approval to expand its label.

“We are surprised and disappointed” that the drug did not show superiority over the placebo, Chief Executive Officer John Kollins said.